AmnioAMP Reapplication Schedule & Storage FAQ

AmnioAMP Reapplication Cadence and Storage: Quick Answers for Clinic Staff

Staff scheduling, inventory, and patient calls all hinge on the same two operational questions: how often does AmnioAMP-MP get reapplied, and how is it stored between visits. The short answers: weekly application is the best-supported cadence for diabetic foot ulcers (DFU), the first reassessment happens at 5–7 days, and the product is dehydrated, room-temperature stable, and needs only a 2–3 minute sterile saline rehydration before use. The longer answers, with the evidence and the storage-compliance detail, are below.

This FAQ is written for the people who actually run the workflow — wound center nurses, office staff, and inventory managers. For the full application sequence, see the AmnioAMP application protocol; for in-office technique detail, see the in-office AmnioAMP-MP technique guide.

---

How often should AmnioAMP be reapplied?

| Wound type | Application cadence | Rationale | Source | |---|---|---|---| | Diabetic foot ulcer | Weekly | Weekly beat biweekly for 12-week closure in a randomized comparison (PMID 24618401) | Zelen et al., Int Wound J | | Venous leg ulcer | Weekly for first 4 weeks, then per response | Early response predicts 24-week closure; continuation beyond a non-response wastes product (PMID 26551645, PMID 38457290) | Serena et al.; Tettelbach et al. | | Other refractory chronic wounds | Weekly to biweekly per clinician judgment | Real-world series used weekly as standard with biweekly variation by wound response (PMID 29634297) | Garoufalis et al., JAPMA |

---

What follow-up schedule should we book?

Book three touchpoints per episode of care:

- Day 5–7: check graft uptake, exudate, periwound skin, and dressing adequacy. If less than half the graft appears integrated or the wound bed is exposed, plan reapplication at this visit rather than waiting. - Day 12–14: measure wound-area reduction and look for epithelialization and granulation. Stall or worsening here is a trigger to reassess the fundamentals — perfusion, infection control, offloading — before more applications. - Week 4: formal response assessment. Percent wound-area change over 4 weeks is a robust predictor of 12-week healing in DFU (PMID 16799391); if the wound is not on a closure trajectory at 4 weeks, escalate the workup rather than adding grafts.

---

How is AmnioAMP stored, and does it need refrigeration?

Storage still carries compliance obligations. Under FDA Current Good Tissue Practice (21 CFR 1271.260), HCT/Ps must be stored within established, documented temperature limits, and any excursion must be recorded, investigated, and resolved before the product returns to available inventory. AATB Standards for Tissue Banking supply the chain-of-custody and handling framework. Practical steps for clinic staff:

- Verify package integrity and expiration on receipt, at stocking, and again in the procedure room before opening — a three-point check. - Rotate stock first-expired-first-out (FEFO), not first-in-first-out. - Record lot number, expiration, and quantity for every unit received, applied, or discarded (21 CFR 1271.265(e), 1271.270). - Never apply an expired unit, and never return an expired or compromised unit to available inventory.

For the full handling sequence including disposal and tissue-tracking requirements, see the amniotic membrane graft handling and storage protocol.

---

How long does rehydration take, and what solution do we use?

Rehydrate the dehydrated sheet in room-temperature sterile 0.9% sodium chloride for 2–3 minutes, until pliable. Handle with atraumatic forceps once rehydrated — the wet sheet is thinner and tears more easily than the dry form. Do not over-soak; prolonged immersion may leach matrix-bound signaling proteins. Do not rehydrate in povidone-iodine, hydrogen peroxide, Dakin's solution, or any other cytotoxic agent — residual antiseptic impairs graft integration. Apply promptly after rehydration; do not leave the graft soaking on the sterile field. If the manufacturer IFU specifies different parameters, the IFU controls.

---

Frequently Asked Questions

Weekly is the best-supported cadence for DFU (PMID 24618401; PMID 30136445). Biweekly application underperformed weekly in the randomized comparison, and weekly application for the first four weeks is the standard opening cadence in VLU protocols (PMID 38457290).

First dressing check at day 5–7 for graft uptake; formal response assessment at week 4. Four-week wound-area change predicts 12-week healing in DFU (PMID 16799391), and 4-week dHACM response predicts 24-week closure in VLU (PMID 26551645).

No. It is dehydrated and room-temperature stable (15–30 °C). No freezer, dry ice, thaw step, or cold-chain validation is required.

2–3 minutes in room-temperature sterile saline, per the application protocol and manufacturer IFU. Apply promptly once pliable.

No. Unused trimmed tissue is discarded, not saved for later application. Document the waste with lot number and quantity per your tissue-tracking log (21 CFR 1271.290).

Remove it from available inventory, quarantine it, and dispose of or return it per the manufacturer's instructions. Expired human tissue must never be applied, and the disposition must be documented.

Weekly cadence is what the randomized evidence tested, and it outperformed stretching visits to every two weeks (PMID 24618401). Keeping the schedule preserves the biological signaling continuity the graft provides and lets the team catch stalled wounds at the week-4 checkpoint instead of weeks later.

See the AmnioAMP application protocol and the in-office technique guide. Product background is in the AmnioAMP product overview, and clinical outcomes detail is in the DFU case series review and the AmnioAMP vs Rampart comparison.

---

About NextGen Biologics USA

NextGen Biologics USA distributes AmnioAMP-MP (single-layer dehydrated human amniotic membrane, HCPCS Q4250) and Rampart DL Matrix (dual-layer dehydrated amniotic membrane, HCPCS Q4347) — both room-temperature-stored, minimally manipulated Section 361 HCT/Ps for homologous use as wound coverings. For product information and samples, visit the NextGen Biologics USA product page.

---

References

1. Zelen CM, Serena TE, Snyder RJ. A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014. PMID: 24618401. 2. Tettelbach W, et al. A confirmatory study on the efficacy of dehydrated human amnion/chorion membrane dHACM allograft in the management of diabetic foot ulcers: a prospective, multicentre, randomised, controlled study of 110 patients from 14 wound clinics. Int Wound J. 2019. PMID: 30136445. 3. Serena TE, et al. Dehydrated human amnion/chorion membrane treatment of venous leg ulcers: correlation between 4-week and 24-week outcomes. J Wound Care. 2015. PMID: 26551645. 4. Tettelbach WH, et al. Dehydrated human amnion/chorion membrane to treat venous leg ulcers: a cost-effectiveness analysis. J Wound Care. 2024. PMID: 38457290. 5. Sheehan P, et al. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Plast Reconstr Surg. 2006. PMID: 16799391. 6. Garoufalis M, et al. Use of dehydrated human amnion/chorion membrane allografts in more than 100 patients with six major types of refractory nonhealing wounds. J Am Podiatr Med Assoc. 2018. PMID: 29634297. 7. FDA. Current Good Tissue Practice, 21 CFR Part 1271 Subpart D (storage, 1271.260; records, 1271.265(e), 1271.270; tracking, 1271.290). 8. American Association of Tissue Banks. Standards for Tissue Banking (handling and chain-of-custody). 9. Manufacturer Instructions for Use, AmnioAMP-MP (rehydration, sizing, and application parameters).

---